Our Commitment to Quality, Transparency, and Continuous Improvement
At GenoGenix, patient safety, product quality, and regulatory compliance are the foundation of everything we do.
Recently, the U.S. Food and Drug Administration (FDA) issued a warning letter related to a prior inspection of our facility. The pharmaceutical outsourcing facility industry operates under one of the most rigorous regulatory frameworks in healthcare, and FDA oversight—including inspections, observations, and warning letters—plays an essential role in maintaining high industry standards and protecting public health.
FDA inspections are a normal part of operating in a highly regulated pharmaceutical industry. These inspections are intended to evaluate compliance, identify areas for improvement, and help protect patients. FDA describes warning letters as advisory actions used to notify firms of any perceived violations and give them an opportunity to correct them, and FDA inspections are a standard part of its oversight activities. Observations described in warning letters typically reflect a specific inspection period and may evolve as companies implement corrective actions and continue working with the agency. We take that process seriously and understand that these findings reflect a point in time during an ongoing review and remediation process.
At GenoGenix, we view regulatory feedback as an opportunity to further strengthen our operations and continuously improve our quality systems. 
Our Response
GenoGenix continues to take the observations identified during the inspection extremely seriously.
Since the inspection, our team has implemented a series of corrective actions and remediation initiatives across several areas of our operations, including quality systems, documentation practices, training programs, and manufacturing procedures.
We have also maintained continuous and proactive communication with the FDA, submitting monthly updates on our remediation progress and corrective action milestones as we address the observations raised during the inspection. Our focus has been on timely remediation, meaningful operational improvements, and continued transparency with the agency throughout that work.
Our goal throughout this process has been straightforward:
- Identify areas for improvement
- Implement corrective actions quickly and thoroughly
- Maintain transparency with regulators
- Strengthen our quality systems for the long term
Strengthening Our Quality Systems
Following the inspection, GenoGenix initiated a comprehensive review of our operations to further strengthen our quality and compliance infrastructure.
Actions underway include:
- Enhancing employee training programs and documentation procedures
- Expanding our quality and regulatory compliance team
- Updating manufacturing processes and quality control systems
- Implementing additional oversight and validation procedures
These improvements build upon steps we previously shared following the FDA audit, including expanded quality programs and operational improvements across the organization. Our objective is not only to address the inspection observations, but also to continue strengthening the systems, controls, and infrastructure that support long-term product quality and patient safety. 
Investing in the Future: A New State-of-the-Art Facility
As part of our long-term commitment to quality and compliance, GenoGenix is currently building a new state-of-the-art outsourcing facility designed to meet the highest modern standards for sterile pharmaceutical compounding.
This facility will incorporate:
- Advanced cleanroom infrastructure
- Modern sterile manufacturing technology
- Expanded quality control laboratories
- Enhanced environmental monitoring systems
- Improved workflow and process controls
This investment reflects our commitment not only to addressing current regulatory expectations but also to building the next generation of pharmaceutical compounding capabilities.
Commitment to Physicians and Patients
GenoGenix remains deeply committed to supporting healthcare providers and protecting patient safety.
Our priorities remain clear:
- Maintaining high manufacturing and quality standards
- Strengthening regulatory compliance systems
- Investing in advanced facilities and infrastructure
- Maintaining transparency with regulators and healthcare partners
We will continue working closely with regulators and compliance partners as we complete our remediation efforts and continue improving our quality systems.
We appreciate the continued trust placed in GenoGenix and remain committed to delivering the highest standards of quality, safety, and integrity.